|
KMID : 1007320090150030135
|
|
Journal of the Korean Society of Menopause
2009 Volume.15 No. 3 p.135 ~ p.144
|
|
|
The Efficacy and Safety of Transdermal Estrogen Therapy
|
|
Yi Kyong-Wook
|
|
|
Abstract
|
|
|
|
Hormone therapy (HT) has been used for many years to treat menopausal symptoms that are related to estrogen deficiency; hot flushes, night sweats, genital atrophy, and bone loss (osteopenia and osteoporosis). Over the last few years, the number of possible HT options has increased, and transdermal delivery systems, such as gels, patches, and creams, have also been developed. Percutaneous administration of estrogen circumvents the hepatic first-pass metabolism, and so this avoids the fluctuations in plasma hormone levels and it permits the use of lower doses of estradiol. Clinically, the transdermal route for administering estradiol is comparable to the presently existing therapies to treat menopause symptoms, and the transdermal route may have additional benefits on the cardiovascular system due to the beneficial effect on the plasma triglyceride, the glucose and insulin metabolism. Postmenopausal women with intolerance to the oral route are primarily indicated for transdermal estrogen therapy. The women with hypertriglyceridemia, those at a high risk for or who have had previous cholelithiasis, and those with persistent or recurring symptoms due to fluctuating levels of plasma estradiol should also be considered for transdermal estrogen therapy.
|
|
|
KEYWORD
|
|
|
Transdermal estrogen, Hormone therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|